Find out more about how RYDAPT is given with your chemotherapy treatment.
For U.S. Residents Only
RYDAPT® (midostaurin) capsules is an oral prescription medicine used in combination with certain chemotherapy medicines to treat adults with newly diagnosed FLT3-positive acute myeloid leukemia (AML). It is the only treatment that is approved by the FDA to treat patients with newly diagnosed AML and the FLT3+ mutation, along with chemotherapy.
RYDAPT is a type of targeted therapy that is given, along with standard chemotherapy, to treat newly diagnosed FLT3+ AML. It is not chemotherapy.
RYDAPT is thought to work by blocking the signals that help certain cells grow and divide. Blocking these signals may help kill leukemia cells in the blood and bone marrow.
RYDAPT is only for adult patients who are newly diagnosed with AML and have a FLT3 genetic mutation. After your initial AML diagnosis, your doctor will order a test for the FLT3 mutation. If you test positive for FLT3, your doctor may prescribe RYDAPT for you in addition to chemotherapy.
AML is a disease that can get worse very quickly. That means your doctor will likely start your treatment right away in the hospital. Treatment usually consists of two phases.
This first phase of treatment is called induction therapy. The goals of induction therapy are to kill as many leukemia cells as possible, get your blood counts back to normal, and put your disease in remission for a period of time. Remission means that some or all signs and symptoms of the cancer have disappeared. However, the disease may still be in your body.
If the disease is still in your body after the induction phase, your doctor may give you additional treatment. This second treatment phase is called consolidation therapy. This treatment can be given while you are in the hospital or as outpatient therapy. Your doctor will discuss what the best treatment plan for you may be.
View the support offerings for eligible patients taking RYDAPT (PDF).